Blood and Lymph Conditions

All Conditions

Neoplasms

Heart and Blood Diseases

Rare Diseases

Myeloproliferative Disorders

Polycythemia Vera

Polycythemia

Thrombocytosis

Thrombocythemia, Essential

Bone Marrow Diseases

Hematologic Diseases

Bone Marrow Neoplasms

Hematologic Neoplasms

Blood Platelet Disorders

Hemostatic Disorders

Blood Coagulation Disorders

Hemorrhagic Disorders

Chronic Myeloproliferative Disorders

Essential Thrombocythemia

Antineoplastic Agents

Antisickling Agents

All Drugs and Chemicals

Hydroxyurea

ET or PV patients diagnosed before acceleration phase and treated by hydroxyurea with a follow up period of at least 6 months following treatment start, with a RNA sample of total leukocytes before start of treatment available

RNA sample of total leukocytes before start of treatment

Olivier MANSIER, Doctor

The aim of this study is to evaluate the endoplasmic reticulum stress markers as predictive for response to hydroxyurea in polycythemia vera (PV) and essential thrombocythemia (ET).

The recent discovery of calreticulin mutations in myeloproliferative neoplasms point to the unexpected role of the endoplasmic reticulum biology in the pathophysiology in these diseases. Otherwise, the association of endoplasmic reticulum stress with solid cancers, in particular in resistance to chemotherapy, is well documented, contrary to hematological malignancies. The study aims to evaluate endoplasmic reticulum stress markers as predictors for the response to hydroxyurea in polycythemia vera and essential thrombocythemia patients. The main objective is to correlate endoplasmic reticulum stress (defined as splicing of XBP1 above 30%) to the rate of complete response after 6 months according to the 2009 ELN criteria. This is an observational retrospective study.

Endoplasmic Reticulum Stress and Resistance to Treatments in Ph-negative Myeloproliferative Neoplasms

University Hospital, Bordeaux

Skin and Connective Tissue Diseases

Symptoms and General Pathology

Immune System Diseases

Melanoma

Neoplasm Metastasis

Hypersensitivity

Neuroendocrine Tumors

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Neoplasms, Germ Cell and Embryonal

Neoplasms by Histologic Type

Neoplasms, Nerve Tissue

Nevus, Pigmented

Nevus

Nevi and Melanomas

Skin Neoplasms

Skin Diseases

Neuroendocrine Tumor

Neuroepithelioma

This research program is in keeping with the chemistry/biology/clinical interface and gathers 4 teams with complementary expertise in these respective fields. It will allow deciphering the mechanism(s) of action of new Thiazole-Benzenesulfonamide family (TZB) derivatives on metastatic melanoma sensitive and resistant to BRAF and MEK inhibitors. Investigators will use melanoma cell lines and primary cells from patients to validate these compounds in collaboration with clinical team 2 and 4. In conclusion, the investigators expect to establish the proof of concept that this new class of bioactive molecules (first in class) we developed in collaboration with Team 3 have the potential to go to the clinic for the treatment of highly aggressive cancers and particularly metastatic melanoma sensitive and resistant B-Raf and MEK inhibitors. Furthermore, the realization of this project can undoubtedly increase the knowledge of mechanisms and signaling pathways that are involved in resistant to BRAF and MEK inhibitors, and allow the selection of drug candidates capable of restoring the sensitivity of these melanoma cells.

biopsy of a target lesion (skin, lymph node or visceral metastases)

Preclinical Validation of New Anti-melanoma Compounds

Preclinical Validation of New Anti-melanoma Compounds: Study on Patient Melanoma Cells Sensitive and Resistant to BRAF/MEK Inhibitors

The status of the BRAF mutation will be expressed through laboratory analysis of the samples collected, i.e. positive or negative.

Centre Hospitalier Universitaire de Nice

Central Nervous System Depressants

Platelet Aggregation Inhibitors

Anesthetics

Propofol

Sevoflurane

Hypnotics and Sedatives

Anesthetics, Intravenous

Anesthetics, General

Anesthetics, Inhalation

Seong-Hyop Kim, Professor

Investigate the change in endoplasmic reticulum stress after cancer surgery according to different anaesthetics including propofol and sevoflurane.

We hypothesize propofol and sevoflurane based anesthesia would show different pattern of endoplasmic reticulum stress after cancer surgery in patients with cancer

Effect of Anaesthesia on ER Stress in Cancer Patients

Evaluation the Effects of Anaesthetic Agents on Endoplasmic Reticulum Stress During Cancer Surgery

Konkuk University Medical Center

Professor

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Endoplasmic Reticulum Stress and Resistance to Treatments in Ph-negative Myeloproliferative Neoplasms	NCT02823184	Polycythemia Ve... Essential Throm...	RNA sample of t...	18 Years -	University Hospital, Bordeaux
Preclinical Validation of New Anti-melanoma Compounds	NCT03798977	Melanoma		18 Years -	Centre Hospitalier Universitaire de Nice
Effect of Anaesthesia on ER Stress in Cancer Patients	NCT03561831	Endoplasmic Ret...	Propofol Sevoflurane	20 Years -	Konkuk University Medical Center

Spots Global Cancer Trial Database for endoplasmic reticulum stress